Device Trial Radar · NCT04011722
Portico Next Generation Approval Study
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
333
Actual
Start
Sep 17, 2019
Primary completion
Jan 12, 2023
Study completion Jan 2033
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jul 8, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.
Conditions
- Symptomatic Severe Aortic Stenosis
Interventions
Portico™ NG (Navitor) Valve and FlexNav™ Delivery SystemDevice
Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery SystemDevice
Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety Endpoint is All-cause MortalityTime frame: at 30 days
- Primary Effectiveness Endpoint is Moderate or Greater Paravalvular LeakTime frame: at 30 days
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Los Robles Regional Medical Center
Thousand Oaks, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
25 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.